Oncology companies develop therapies, diagnostics and technologies that support the detection, monitoring and treatment of cancer. The sector is one of the largest and most active areas of biotechnology and pharmaceutical innovation.
This category includes companies working on:
Browse 291 UK oncology companies below.
Molecular and digital biomarkers for personalised cancer treatment
Oxford Cancer Biomarkers is a precision oncology diagnostics company developing molecular and digital pathology tests to support personalised cancer treatment. Its pharmacogenomic assays assess inherited variants associated with fluoropyrimidine chemotherapy toxicity, while its algorithm-driven pathology tools analyse…
Complex molecule synthesis and chemistry-driven cancer drug discovery
New Path Molecular Research is a Cambridge-based chemistry company spun out from the laboratory of Professor Steve Ley at the University of Cambridge. The company specialises in the synthesis of complex functional molecules, including natural products, macrocycles and peptides, using flow chemistry and…
Galectin-3 targeted small molecule therapeutics for cancer and fibrosis
Galytx is a University of Liverpool spin-out developing small molecule therapeutic drugs that target galectin-3, a protein closely associated with cancer, fibrosis and inflammatory disease. The company's portfolio includes a repurposed clinical-stage asset with an established safety record, alongside pre-clinical…
Precision oncology biotech targeting synthetic lethality in cancer
Tessellate Bio is a precision oncology company developing small molecule drugs that exploit synthetic lethality, the principle that certain genetic vulnerabilities in cancer cells can be targeted to selectively kill tumour cells. The company's lead programme targets the FANCM complex in cancers relying on Alternative…
Molecular assay platform for genomic profiling in cancer diagnostics
Biofidelity is a Cambridge-based genomic technology company developing molecular assays for cancer biomarker detection in tissue and liquid biopsy samples. Its proprietary platform enables ultra-sensitive detection of somatic mutations at low variant allele fractions using a simplified four-step qPCR workflow, without…
Specialist oncology clinical trial management for biotech and pharma
Karma Oncology is a specialist contract research organisation providing full-service and functional clinical trial management to biotechnology and pharmaceutical companies in oncology. Operating as a lean virtual CRO, the company offers clinical development planning, protocol design, site selection and activation,…
Bispecific TCR therapies targeting HLA-Class II cancer antigens
Yellowstone Biosciences is a pre-clinical biotechnology company developing bispecific T-cell receptor therapies for oncology. The company targets a novel class of HLA Class II antigens expressed across multiple cancers, with an initial programme focused on acute myeloid leukaemia. Its approach is designed to…
Integrated drug discovery CRO from target to clinical candidate
Sygnature Discovery is a UK-headquartered integrated drug discovery contract research organisation. Operating from sites in Nottingham, Alderley Park, and Glasgow, the company provides end-to-end drug discovery services spanning target identification, medicinal chemistry, in vitro bioscience, structural biology,…
Non-invasive vaginal sampling for gynaecological disease
Ellele Health is a medical research company developing a minimally invasive vaginal sampling device and associated downstream assays for the detection and management of gynaecological conditions. Using a proprietary biospecimen collected from the vaginal wall, the company applies genetic, epigenomic, and microbial…
IgE and IgA antibody therapeutics for cancer treatment
Epsilogen is a clinical-stage biotech pioneering the development of non-IgG immunoglobulin antibody therapeutics for cancer. The company's platform spans IgE, IgA, and IgG isotypes, enabling selection of the most appropriate antibody format for a given tumour type. Its lead candidate MOv18 IgE, the first IgE antibody…
Bispecific antibody platform for cancer immunotherapies
F-star Therapeutics is a clinical-stage biotechnology company developing tetravalent bispecific antibodies for cancer and other serious diseases. Its proprietary platform creates antibodies with four binding sites that simultaneously target two different antigens, enabling focused immune activation in the tumour…
AI and quantum-chemical platform for small-molecule drug design
Tres Alchemix is the UK subsidiary of a Japanese biotechnology company developing an AI-driven drug-design platform for small-molecule therapeutics. The platform integrates quantum-level chemical calculations with AI models trained on biochemical and pharmacological datasets to predict the efficacy and safety of novel…
Integrated academic drug discovery facility for anti-infectives and innovative targets
The Drug Discovery Unit is an academic drug discovery facility at the University of Dundee, integrating medicinal chemistry, high-throughput screening, structural biology, cell biology, and DMPK in a single purpose-built facility. The DDU conducts small molecule drug discovery programmes across two areas:…
Therapeutic cancer vaccines based on recombinant overlapping peptide technology
Oxford Vacmedix is a clinical-stage biopharma company developing therapeutic cancer vaccines using its proprietary Recombinant Overlapping Peptide (ROP) platform. ROPs stimulate broad T cell and antibody immunity without HLA restriction, enabling a universal immunotherapy approach. The lead programme, OVM-200, targets…
Systemic viral immunotherapy for solid tumours
Stratosvir develops engineered viral immunotherapies for advanced solid tumours and their metastases. Its platform aims to overcome the limitations of injecting therapeutic viruses directly into tumours by enabling systemic, intravenous delivery. Within tumour tissue, the viruses are designed to replicate selectively…
CAR T cell therapies for blood cancer and autoimmune disease
Autolus Therapeutics is a London-based commercial-stage biopharma developing next-generation programmed T cell therapies. Its lead product AUCATZYL (obecabtagene autoleucel) received FDA approval in November 2024 and MHRA conditional marketing authorisation in 2025 for relapsed or refractory B-cell acute lymphoblastic…
AI-driven liquid biopsy platform for early cancer biomarker discovery
BioMavericks is an early-stage biotechnology company developing an AI-driven liquid biopsy platform for the early detection of cancer. Its lead product targets the discovery and validation of blood-based biomarkers for early-stage pancreatic cancer diagnostics, integrating molecular cell biology, multi-omics data…
GPCR-targeted small molecule drugs for rare and inflammatory disease
Trio Medicines is a small pharmaceutical company developing small molecule therapeutics targeting G-protein coupled receptors for diseases with unmet clinical need. Its pipeline includes gastrin/CCK2 receptor antagonists for gastric neuroendocrine tumours, a selective β2-adrenoceptor antagonist, and a formyl peptide…
Antibody therapeutics targeting glycosphingolipid inflammation
Protalea Bio is a biotech company developing first-in-class therapeutic antibodies to prevent progression from precancerous states to active blood cancers including multiple myeloma and B-cell lymphoma. The company's approach targets glycosphingolipid-related inflammation before disease onset, building on over fifteen…
DNA methylation blood tests for ovarian and pancreatic cancers
GenoME Diagnostics is a biotechnology company developing molecular blood tests for cancer detection and monitoring. Its liquid biopsy platform identifies DNA methylation and fragmentomic biomarkers, combining them into multiplexed droplet digital PCR assays. Its lead test targets ovarian cancer recurrence and…